VerbaFlo.AI | $7,000,000 | (Mar 18, 2026)
Surf AI(1) | $57,000,000 | (Mar 18, 2026)
R1 Therapeutics | $77,500,000 | (Mar 18, 2026)
Certified by Founder
Lodge
DotBio
start up
Singapore
- Singapore
- 07/08/2023
- Pre Series A
- $5,600,000
DotBio is focused on the development of novel immuno-oncology drugs based on humanized domain antibodies, its proprietary DotBody technology. DotBodies are domain therapeutic antibodies which are multi-specific, humanized and highly-stable. The company was founded by Professor Pär Nordlund and Dr. Ignacio Asial, who designed and conceptualized the DotBody technology based on their expertise in protein and antibody engineering at Singapore’s Nanyang Technological University. For more information visit www.dotbiopharma.com
- Industry Biotechnology Research
- Website https://www.dotbio.com/
- LinkedIn https://www.linkedin.com/company/dotbio/about/
Quorus | $5,000,000 | (Mar 18, 2026)
BambooBox | $6,600,000 | (Mar 18, 2026)
iDEL Therapeutics GmbH | $10,381,635 | (Mar 18, 2026)
Conduit Health | $17,000,000 | (Mar 18, 2026)
SEQUENTIAL | $3,500,000 | (Mar 18, 2026)
Standard Template Labs | $49,000,000 | (Mar 18, 2026)
Tenkara | $7,000,000 | (Mar 18, 2026)
Turquoise(US) | $40,000,000 | (Mar 18, 2026)
AgZen | $10,000,000 | (Mar 17, 2026)